Sandoz in-licenses authorized generic of Proventil HFA

17 March 2021

Sandoz Inc has in-licensing of commercial distribution rights to the brand and authorized generic of respiratory inhalation medicine Merck & Co’s (NYSE: MRK) Proventil HFA (albuterol sulfate) Inhalation Aerosol from Kindeva Drug Delivery, a global contract development and manufacturing organization supplying the product.

The albuterol sulfate authorized generic, a treatment for respiratory diseases, is immediately available to patients in the USA, said Sandoz, the generics and biosimilars arm of Swiss pharma giant Novartis (NOVN: VX).

There has been a surge in demand for albuterol medicines over the past year. Hospitals increasingly switched to using metered-dose albuterol inhalers rather than nebulizers to treat the growing number of COVID-19 patients. Pharmacies also saw increased demand for albuterol inhalers after the Centers for Disease Control and Prevention ( CDC) recommended that Americans stock up on necessary medications.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK